Edition:
United Kingdom

Viking Therapeutics Inc (VKTX.OQ)

VKTX.OQ on NASDAQ Stock Exchange Capital Market

10.54USD
16 Aug 2018
Change (% chg)

$0.11 (+1.05%)
Prev Close
$10.43
Open
$10.49
Day's High
$10.58
Day's Low
$10.28
Volume
329,734
Avg. Vol
593,081
52-wk High
$13.40
52-wk Low
$0.97

Chart for

About

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip... (more)

Overall

Beta: --
Market Cap(Mil.): $57.61
Shares Outstanding(Mil.): 27.70
Dividend: --
Yield (%): --

Financials

  VKTX.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.83 -- --
ROI: -183.94 1.78 14.61
ROE: -184.23 3.28 16.33

BRIEF-Viking Therapeutics Q1 Loss Per Share $0.08

* VIKING THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

09 May 2018

BRIEF-Viking Therapeutics Q4 Loss Per Share $0.14

* VIKING THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

07 Mar 2018

Earnings vs. Estimates